Efeito da suplementação de colecalciferol nos RNA mensageiros urinários associados ao podócito em pacientes com doença renal crônica by Timm, João Rodolfo Teló et al.
Original article | artigO Original
173
Authors
João Rodolfo Teló Timm 1
Cristina Karohl 1
Mariane dos Santos 1
Maysa Lucena de Souza 1
Rafael Zancan 1
Rafael de Almeida 2
Francisco Veríssimo 
Veronese 1,3
1 Universidade Federal do 
Rio Grande do Sul.
2 Universidade Federal de 
Pelotas.






Hospital de Clínicas de Porto 
Alegre.
Rua Ramiro Barcelos, nº 2350, 




Effect of cholecalciferol supplementation on urine podo-
cyte-associated messenger RNAs in patients with chronic 
kidney disease
Efeito da suplementação de colecalciferol nos RNA mensageiros 
urinários associados ao podócito em pacientes com doença renal 
crônica
Introdução: A vitamina D reduz a albu-
minúria em pacientes com doença renal 
crônica (DRC), mas o seu efeito sobre os 
podócitos glomerulares ainda não é claro. 
Objetivos: Avaliar se a suplementação de 
colecalciferol reduz os RNAm urinários 
associados ao podócito em pacientes com 
DRC. Métodos: Vinte e sete pacientes com 
DRC estágios 2 a 4 e níveis sub-ótimos de 
25-hidroxi-vitamina D [25(OH)D] sérica 
foram tratados com colecalciferol por seis 
meses. Foram medidos antes e após a in-
tervenção a 25(OH)D sérica e o RNAm 
urinário da nefrina, podocina, podoca-
lixina, receptor transitório potencial do 
canal de cátions, subfamília C, membro 
6 (TRPC6), fator A de crescimento do en-
dotélio vascular (VEGF-A) e fator de cres-
cimento transformador beta (TGF-β1). 
Resultados: A TFGe reduziu em média 
4,71 mL/min/1,73 m2 (p = 0,010 vs. bas-
al), sendo 28 ± 16 mL/min/1,73 m2 aos seis 
meses. Os RNAm dos produtos do podó-
cito na urina não tiveram alteração sig-
nificativa após o tratamento. Entretanto, 
pacientes que atingiram níveis de 25(OH)
D ≥ 20 ng/mL aos 6 meses tiveram tendên-
cia de redução do RNAm da nefrina e da 
podocina na urina; nos pacientes em que a 
25(OH)D permaneceu < 20 ng/mL houve 
aumento significativo da podocalixina, e 
tendência de maior expressão do RNAm 
da nefrina e da podocina. Conclusão: A 
reposição de colecalciferol por seis meses 
não teve efeito sobre os RNAm associad-
os ao podócito nestes pacientes com DRC 
avançada. O efeito protetor da vitamina 
D ou seus análogos sobre o podócito glo-
merular deve ser investigado em estágios 
mais precoces da DRC e com maior tem-
po de tratamento.
Resumo
Palavras-chave: fator A de crescimento do 
endotélio vascular; fator de crescimento 
transformador beta1; insuficiência renal 
crônica; podócitos; vitamina D.
Introduction: Vitamin D reduces albuminuria 
in patients with chronic kidney disease (CKD) 
but its effects on glomerular podocytes 
are not entirely understood. Objective: To 
evaluate if cholecalciferol supplementation 
reduces the levels of podocyte-associated 
urine mRNAs in patients with CKD. 
Methods: A total of 27 patients with stages 
2 to 4 CKD and suboptimal serum vitamin 
D [25(OH)D] levels were treated with 
cholecalciferol for 6 months. Serum 25(OH)
D level, estimated glomerular filtration rate 
(eGFR), proteinuria, and urine mRNA of 
nephrin, podocin, podocalyxin, transient 
receptor potential cation channel 6, vascular 
endothelial growth factor A, and transforming 
growth factor beta were assessed before 
and after intervention. Results: eGFR 
declined at an average rate of -4.71 mL/
min/1.73 m2 (p = 0.010 vs. baseline), being 
28 ± 16 mL/min/1.73 m2 at six months. No 
changes in proteinuria or mineral and bone 
metabolism parameters were observed after 
cholecalciferol supplementation. Urinary 
podocyte-associated mRNAs did not change 
significantly after treatment. However, 
patients who achieved 25(OH)D level > 
20 ng/mL at six months showed a trend of 
reduction of urinary nephrin and podocin 
mRNA levels; in patients with 25(OH)D that 
remained < 20 ng/mL there was a significant 
increase in urinary podocalyxin, and a trend 
of higher expression of urinary nephrin and 
podocin mRNA. Conclusion: Six months 
of cholecalciferol supplementation had no 
effect on urine podocyte-associated mRNA 
profile of patients with advanced CKD. 
The protective effect of vitamin D or its 
analogues on the glomerular podocyte 
should be investigated in early stages of 
CKD with a longer treatment period.
AbstRAct
Keywords: podocytes, renal insufficiency, 
chronic; transforming growth factor 
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IntRoductIon
Suboptimal serum vitamin D level is a common 
finding in patients with chronic kidney disease 
(CKD).1,2 Several observational studies have 
demonstrated an association between vitamin 
D deficiency and increased albuminuria, lower 
glomerular filtration rate (GFR), and higher mortality 
risk.3-5 Both experimental and clinical studies have 
suggested that vitamin D receptor (VDR) activation 
can reduce albuminuria, glomerular hyperfiltration, 
podocyte loss, glomerulosclerosis, interstitial fibrosis, 
and even all-cause and cardiovascular mortality.6-12 
Therefore, vitamin D could have antiproteinuric 
and renoprotective effects possibly through 
different mechanisms, including anti-fibrotic, anti-
inflammatory, and anti-apoptotic inflammatory, and 
anti-apoptotic pathways.13
Active vitamin D and its analogs may reduce 
albuminuria through podocyte protection.7,8 
Experimental studies demonstrated that vitamin D 
1-α-hydroxylase and VDR are expressed on podocyte 
suggesting that these cells are able to synthesize active 
vitamin D, 1.25-dihydroxyvitamin D, which can act 
via paracrine and/or autocrine signaling pathways.14 
1.25-dihydroxyvitamin D interacts intracellularly 
with the VDR, and this complex is translocated to 
the nucleus and binds to vitamin D response elements 
stimulating transcription of slit diaphragm-associated 
proteins such as nephrin and podocin.9,15
In diabetic knockout mice for VDR more renal 
fibronectin and pro-fibrotic factors and less nephrin 
were expressed compared to diabetic wild-type mice, 
while vitamin D administration in culture podocytes 
increased nephrin expression.16 In addition, vitamin 
D attenuated podocyte damage, reducing the index 
of podocyte fusion, apoptosis and loss in urine in 
experimental models of diabetes15 and adriamycin-
induced nephrosis.8
Podocyte detachment, as viable or apoptotic 
cells, leads to podocyte loss in urine and ultimately 
to proteinuria. Podocyturia can be quantified by 
measuring podocyte byproducts or its fragments 
in urine. Although this non-invasive diagnostic 
tool is not yet used in clinical practice, it has been 
suggested that podocyturia can be more accurate 
than proteinuria in the detection of glomerular 
filter damage, disease activity and progression.17 To 
date, no clinical studies have evaluated the effect 
of cholecalciferol supplementation as a protective 
strategy to attenuate podocyte injury in patients with 
established CKD of different etiologies that present 
suboptimal serum levels of 25(OH)D. Therefore, we 
hypothesized that cholecalciferol supplementation 
may reduce urinary excretion of podocyte-associated 
mRNAs in this patient population.
mAteRIAl And methods
This single-center, open-label prospective intervention 
study recruited 27 adult patients with CKD from 
August 2013 to May 2014. Inclusion criteria were 
age ≥ 18 years, estimated GFR (eGFR) between 15 
and 89 mL/min/1.73m2 measured according to the 
Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation,18 stable kidney function in the 
previous three months, protein to creatinine ratio 
(Pr/Cr) in a random urine sample higher than 0.5, 
and a serum concentration of 25(OH)D < 30 ng/
mL. Exclusion criteria were acute intercurrent illness, 
current treatment with immunosuppressive drugs or 
other vitamin D preparations including calcitriol or 
analogs, pregnancy, positivity for HIV, hepatitis B or 
hepatitis C antibodies, and kidney transplantation.
This study was approved by the Research Ethics 
Committee of the HCPA and performed according 
to the 1975 Declaration of Helsinki. All participants 
provided written informed consent prior to enrollment. 
The Research Ethics Committee is registered in the 
Brazilian Human Research Protection Committee of 
the National Ministry of Health under Institutional 
Review Board number 00000921.
InterventIon
All patients received oral cholecalciferol for 6 months 
at doses recommended by Kidney Disease Outcomes 
Quality Initiative (K-DOQI) guidelines.19 Treatment was 
prescribed as follows: a) 25(OH)D < 5 ng/mL: 50.000 IU 
a week for 12 weeks, followed by 10.000 UI a week; b) 
25(OH)D between 5 and 15 ng/mL: 50.000 UI a week 
for 4 weeks, followed by 10.000 UI a week; c) 25(OH)D 
between 16 to 30 ng/mL: 10.000 UI a week.
Serum calcium and phosphorus levels were 
reassessed on the third month of cholecalciferol 
supplementation. If serum calcium was above upper 
normal limits, cholecalciferol supplementation was 
withdrawn. If phosphorus levels were above reference 
values, a phosphate binder was initiated or the 
dose was adjusted (500 to 1000 mg of oral calcium 
carbonate at meals).
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ClInICal CharaCterIstICs and laboratory 
parameters
The following clinical data were collected from each 
participant: age, gender, race, mean systolic (SBP) and 
diastolic blood pressure (DBP), body mass index (BMI) 
calculated by weight and height (kg/m2), etiology of 
CKD, and current medications. Laboratory tests were 
performed at baseline and at 3 and 6 month follow-
up. The following variables were assessed at baseline: 
blood glucose, creatinine, calcium, phosphorus, 
total cholesterol, HDL cholesterol, and triglycerides 
(Spectrophotometric, Roche Diagnostics, Rotkreuz, 
Switzerland), LDL cholesterol (Friedewald formula), 
albumin, intact parathyroid hormone measured by 
chemiluminescence (Global Siemens Headquarters, 
Muenchen, Germany). Serum and urine creatinine 
were measured using the Jaffe reaction (Modular 
P Roche Diagnostic, Mannheim, Germany). eGFR 
was calculated using the CKD-EPI formula, and 
proteinuria was quantified using the Pr/Cr. Serum 
25(OH)D levels were evaluated using the DiaSorin 
25OH Vitamin D immunoassay on a LIAISON™ 
auto-analyzer (DiaSorinInc, Northwest, MN, USA). 
Calcium and phosphorus levels were reassessed at 
3 months, and serum intact parathyroid hormone, 
calcium, phosphorus, 25(OH)D, and creatinine levels 
and urinary Pr/Cr were reassessed at 6 months.
podoCyte-assoCIated mrna levels
Podocyte-associated mRNA expression in the urinary 
sediment cells of a morning urine sample (whole 
stream) was determined by real-time polymerase 
chain reaction (RT-PCR), as previously described.20 
Samples were screened for the following mRNA 
transcripts: nephrin, podocin, podocalyxin, transient 
receptor potential cation channel 6 (TPC6), vascular 
endothelial growth factor (VEGF-A) as an endothelial 
proliferation marker, and transforming growth factor 
beta (TGF-ß1) as a marker of intra-renal fibrosis. 
Messenger RNA levels were measured at baseline and 
after six months of cholecalciferol supplementation.
In brief, mRNA was extracted using the QIAmp™ 
RNA Mini Kit (Qiagen Inc. Chatsworth, CA, USA), 
according to the manufacturer’s instructions. Total 
RNA was quantified using a NanoDrop™ 1000 
Spectrophotometer v.3.7 (Thermo Fisher Scientific, 
DE, USA) and RNA purity was determined by 
the ratio of absorbance at 260 and 280 nm ratio. 
RNA was reverse-transcribed using the cDNA High 
Capacity Kit (Applied Biosystems, Foster City, CA, 
USA), according to manufacturer’s instructions, 
until a volume of 20 μL was achieved. RT-PCR was 
performed using a Taqman Universal PCR Master 
Mix, containing AmpliTaq Gold™ DNA polymerase, 
Amperase UNG, passive reference (ROX), buffer 
solution and dNTPs (Applied Biosystems, Foster 
City, CA, USA), in addition of specific primers 
for the amplification of the following genes: 
NPSH1, nephrin (ID:Hs00190446_m1); NPSH2, 
podocin (ID:Hs00387817_m1); podocalyxin 
(ID:Hs01574644_m1); TRPC6 (ID:Hs00989190_
m1); VEGF-A (ID:Hs00173626_m1) and TGF-ß1 
(ID:Hs00998133_m1), according to manufacturer 
instructions (Applied Biosystems, Foster City, CA, 
USA). 18s rRNA (Taqman™ PDAR) was used as 
an endogenous control. RT-PCR was performed in 
duplicate in 96-well plates containing 2 μL cDNA.
Reactions were cycled at 50ºC for 2 minutes, 60ºC 
for 30 minutes followed by denaturation at 95ºC for 
5 minutes, and 40 cycles at 94ºC for 20 seconds and 
62ºC for 60 seconds. Amplification was performed 
in an ABI PRISM 7000 SDS thermocycler (Applied 
Biosystems, Foster City, CA, USA). The relative 
quantification of target gene expression was perfor-
med using the 2-ΔΔct comparative method where CT 
(threshold cycle) value is defined as the point where 
a statistically significant increase in the fluorescence 
has occurred.
stAtIstIcAl AnAlysIs
Continuous variables were described as mean and 
standard deviation (SD) or median and interquartile 
range, while categorical variables were expressed as 
proportions. Normality of distribution was determined 
using the Kolmogorov-Smirnov and Shapiro Wilk 
tests. Messenger RNA values were log-transformed 
to conform to normality assumptions. Continuous 
variables were compared using independent t-test, 
Mann-Whitney or Kruskal Wallis tests. Pre- and 
post-treatment results were compared using paired 
t-tests or Wilcoxon’s signed rank test. The association 
between urinary podocyte-associated mRNAs, serum 
25(OH)D, eGFR and proteinuria was evaluated using 
Spearman correlation coefficients.
The change in mRNA expression after six months 
of cholecalciferol supplementation was analyzed using 
Generalized Estimating Equations (GEE) with a gamma-
logarithmic model and Bonferroni’s correction for 
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multiple comparisons. GEE was used to evaluate between-
group differences and changes over time in addition to 
group-by-time interactions. Results were expressed as 
median and confidence intervals (95%CI). Data were 
analyzed using the SPSS software for Windows (version 
18.0, SPSS Inc., Chicago, IL). Results were considered 
significant at p < 0.05.
Results
demographIC and ClInICal CharaCterIstICs
The demographic and clinical characteristics are 
summarized in Table 1. Ten (37%) patients had chronic 
glomerulonephritis because they were referred from the 
Glomerular Disease outpatient clinic. Fifteen (55.6%) 
patients had stage 4 CKD, while the remainder had an 
eGFR ≥ 30 mL/min/1.73 m2. Approximately half of 
the patients were using angiotensin converting enzyme 
(ACE) inhibitors or angiotensin II receptor antagonists 
(ARA-2). All patients presented with suboptimal serum 
25(OH)D levels (< 30 ng/mL). After six months of oral 
cholecalciferol supplementation, serum 25(OH)D levels 
increased by 90.4% in patients with baseline 25(OH)
D levels < 20 ng/mL (p < 0.001), and a smaller but 
significant 66% increase in serum 25(OH)D was also 
noted in patients with baseline 25(OH)D ≥ 20 ng/mL (p 
= 0.005); those increases reflect the effectiveness of the 
prescribed treatment.
eGFR decreased significantly over the follow-up 
period (-4.71 mL/min/1.73 m2, p < 0.010 vs. baseline). 
Patients with an eGFR between 15-29 mL/min/1.73 
m2 showed serum levels of 25(OH)D of 19.7 ± 6.0 
and 28.9 ± 9.9 ng/mL at baseline and after 6 months, 
respectively (p < 0.001). In patients with an eGFR ≥ 30 
ml/min/1.73 m2, the corresponding values were 18.2 
± 7.2 and 26.7 ± 13.4 ng/mL (p = 0.042). Urine Pr/
Cr did not change after six months of cholecalciferol 
supplementation, as shown in Table 2.
Bone and mineral metabolism parameters (calcium, 
phosphorus and intact parathyroid hormone) did 
not differ between baseline and six-month follow-
up. However, a trend toward increasing levels was 
observed in both parathyroid hormone (p = 0.086) 
and serum calcium (p = 0.084) levels.
podoCyte-assoCIated mrnas expressIon after 
CholeCalCIferol supplementatIon
Urinary excretion of podocyte-associated mRNA 
did not change significantly from baseline to post-
treatment assessment (Table 3). To evaluate the 
effect of achieving higher levels of serum 25(OH)D 
compared to lower levels on the urinary expression 
of podocyte-associated mRNAs, the sample was 
classified according to 25(OH)D status (< 20 ng/
mL or ≥ 20 ng/mL). Also, patients were categorized 
according CKD stage: stage 4 CKD (eGFR 15-29 
mL/min/1.73 m2) or stage 2-3 CKD (eGFR ≥ 30 mL/
min/1.73 m2) at the end of follow up to determine 
if better or worse renal function could account for 
differences in mRNA expression.
Both groups - with higher or lower levels of 25(OH)
D at 6 months - showed a non-significant variation in 
the mRNA expression of podocyte proteins and growth 
factors. Similarly, urinary mRNA expression of podocyte 
proteins and growth factors did not change in patients 
with better kidney function (eGFR ≥ 30 ml/min/1.73 m2).
Although the log10 mRNA of nephrin, podocin 
and podocalyxin (but not of the remaining podocyte 
mRNAs) decreased from baseline to the 6-month 
follow-up, these values did not differ between groups 
or showed group-by-time interactions. This was the 
case for nephrin, whose levels decreased from 4.48 
(3.03-5.93) to 2.79 (1.46-4.12); (p value = 0.08) in 
patients with 25(OH)D ≥ 20 ng/mL, and increased 
from 3.12 (2.41-3.10) to 4.61 (2.83-6.40); (p value 
= 0.07) in patients with 25(OH)D levels < 20 ng/
mL. Podocin mRNA also decreased from 3.43 (2.54-
4.32) to 2.50 (1.21-3.15), (p value = 0.08) in patients 
with 25(OH)D levels ≥ 20 ng/mL, but did not show 
an inverse trend in patients with vitamin D < 20 
ng/mL. Podocalyxin expression did not change in 
patients with higher 25(OH)D levels, but increased 
significantly at follow-up in patients with low serum 
25(OH)D levels: 2.71 (2.10-3.42) vs. 3.63 (2.64-
4.52), (p = 0.009).
Analyzing the expression of each podocyte mRNA 
according to the tertile of serum 25(OH)D levels at baseline 
and after 6 months of cholecalciferol supplementation, 
correlation between higher 25(OD)D levels and lower 
mRNA expression of podocyte-associated mRNAs was 
not observed in any tertile. As shown in Figure 1 and 
Figure 2, the variability of each gene in both periods was 
small across the distribution of 25(OH)D tertiles.
CorrelatIons between podoCyte-assoCIated mrnas, 
25(oh)d, proteInurIa and kIdney funCtIon
Spearman correlations showed no relationship 
between the expression of podocyte-associated 
mRNAs and 25(OH)D levels, either at baseline or 
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N = 27
Age (years) 56 ± 13
Gender (female) 14 (52)
Ethnicity (Caucasian) 17 (63)











SBP (mmHg) 140 ± 21
DBP (mmHg) 86 ± 10
Use of ACE-I 15 (55.5)
Use of ARA-2 14 (51.8)
BMI: Body Mass Index; CKD: Chronic kidney disease; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; ACE-I: Angiotensin-converting 
enzyme inhibitor; ARA-2: angiotensin II receptor antagonist. Values are expressed as mean ± DP or number of patients (%).
tAble 1 ClInICal and demographIC CharaCterIstICs of patIents wIth ChronIC kIdney dIsease
Baseline 6 months p
eGFR (mL/min/1.73m2) 32.74 ± 15.56 28.03 ± 16.30 0.010
Pr/Cr (urine) 2.53 ± 2.14 2.62 ± 2.51 0.855
Serum calcium (mg/dL) 8.83 ± 0.60 8.98 ± 0.68 0.084
Serum phosphorus (mg/dL) 3.70 ± 0.49 3.98 ± 0.74 0.204
Intact PTH (pg/mL) 222 ± 162 286 ± 221 0.086
Serum albumin (g/dl) 4.08 ± 0.30 4.10 ± 0.22 0.101
25(OH)D (ng/mL) 19 ± 7 28 ± 11 0.003
eGFR: estimated glomerular filtration rate; Pr/Cr: protein/creatinine index in random urine sample; PTH: parathyroid hormone. Data are expressed 
as mean ± DP.
tAble 2 laboratory evaluatIon of kIdney funCtIon, proteInurIa, mIneral and bone metabolIsm at baselIne and  
 after CholeCalCIferol supplementatIon
mRNA Baseline 6 months p
Nephrin 3.24 (2.30-4.46)† 2.71 (1.86-3.43) 0.349
Podocin 3.10 (2.25-4.53) 2.60 (1.79-3.89) 0.400
Podocalyxin 2.72 (1.75-3.74) 2.79 (1.97-4.18) 0.109
TRPC6 2.82 (1.93-3.97) 2.53 (1.52-5.46) 0.665
VEGF-A 2.85 (1.82-3.86) 2.41 (1.52-3.83) 0.239
TGF-ß1 3.16 (2.26-3.67) 3.05 (2.32-3.94) 0.923
tAble 3 urInary podoCyte-assoCIated mrnas expressIon at baselIne and after CholeCalCIferol    
 supplementatIon In ChronIC kIdney dIsease patIents
TRPC6: Transient receptor potential cation channel 6; TGF-β1: transforming growth factor beta; VEGF-A: vascular endothelial growth fator. †Median 
and percentiles (P25-P75) of log10 mRNA (2-∆∆ct)
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Figure 1. Urine mRNA of nephrin, podocin, and podocalyxin according to tertiles of serum 25(OH)D - Effects of cholecalciferol supplementation 
on urine mRNA of nephrin, podocin, and podocalyxin according to tertiles of serum 25(OH)D level both before and after intervention. Tertile 1 
included subjects with lowest serum 25(OH)D level (< 23 ng/mL), tertile 2 included subjects with middle 25(OH)D level (23-30 ng/mL), and tertile 
3 included subjects with highest 25(OH)D level (> 30 ng/mL). In the box plots, cross bars and horizontal bars represent median, minimum and 
maximum ranges of each Log10 urine mRNA. There was no significant correlation between 25(OH)D tertiles and mRNA expression of podocyte 
proteins (p value > 0.05).
at the 6-month follow-up. Similarly, no correlations 
were observed between mRNA expression and eGFR 
or proteinuria. Serum 25(OH)D was positively and 
significantly correlated with urinary protein excretion 
both at baseline (r = 0.517, p = 0.008) and at the six-
month follow-up (r = 0.539, p = 0.005).
dIscussIon
The present study did not find an improvement in the 
mRNA profile of podocyte-associated byproducts in 
urine after 6 months of cholecalciferol supplementation. 
Proteinuria did not change as well. However, those with 
higher serum levels of 25(OH)D at 6 months (≥ 20 ng/ml) 
showed a trend toward decreased nephrin and podocin 
expression, while the opposite pattern was observed in 
patients with low 25(OH)D levels.
Recent studies have shown that, in addition to 
its role in calcium and phosphorus metabolism, 
vitamin D is also involved in the regulation of renal, 
cardiovascular and immune functions.21 Clinical 
and experimental studies have found that vitamin D 
decreases urinary albumin excretion and delays the 
progression of kidney disease.10,11,14-16,22 The VDR 
activation by 1,25(OH)2D3 or its analogues triggers 
several signaling pathways involved in podocyte 
protection, such as the inhibition of the renin-
angiotensin system, the attenuation of apoptosis and 
kidney fibrosis, and the increase of podocyte gene 
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Figure 2. Urine mRNA of TRPC6, VEGF-A, and TGF-ß1 according to tertiles of serum 25(OH)D - Effects of cholecalciferol supplementation on urine 
mRNA of TRPC6, VEGF-A, and TGF-ß1 according to tertiles of serum 25(OH)D level both before and after intervention. Tertile 1 included subjects 
with lowest serum 25(OH)D level (< 23 ng/mL), tertile 2 included subjects with middle 25(OH)D level (23-30 ng/mL), and tertile 3 included subjects 
with highest 25(OH)D level (> 30 ng/mL). In the box plots, cross bars and horizontal bars represent median, minimum and maximum ranges of 
each Log10 urine mRNA. There was no significant correlation between 25(OH)D tertiles and mRNA expression of expression of podocyte proteins 
(p value > 0.05).
expression, thus preserving podocyte structure and 
function.7-9,14-16,23,24
In animal models of induced nephropathy, 
vitamin D has been found to decrease the amount of 
podocytopenia, podocyturia, podocyte hypertrophy 
and apoptosis, increase the expression of nephrin, 
podocin, α3β1 integrin and dystroglycan, and suppress 
TGF-β1 and TRPC6 expression.
6,25-28 These findings 
suggest that the combined effects of vitamin D or its 
analogues on the glomerular podocyte may be critical 
for renoprotection, which have significant impact in 
reducing albuminuria and chronic kidney damage.
TRPC6 is a slit diaphragm protein whose 
expression increases as a result of podocyte injury 
in proteinuric nephropathies. ACE inhibitors 
increase TRPC6 expression, as does calcitriol use. 
1,25(OH)2D3 was found to normalize glomerular 
TRPC6 expression, restore podocyte morphology 
and reduce proteinuria in two experimental models 
of induced nephropathy,25,28 probably due to its 
effects on the TRPC6 promoter. In the present 
study, although cholecalciferol supplementation 
increased serum 25(OH)D, the intervention had 
no effect on TRPC6 expression in urine, regardless 
25(OH)D serum levels or a better or worse 
glomerular filtration rate. However, unlike the 
previously mentioned studies, we did not measure 
gene transcription and TRPC6 mRNA in kidney 
tissue, since it would be unethical to biopsy these 
patients.
J Bras Nefrol 2016;38(2):173-182
Effect of vitamin D on urine podocytes
180
Low serum 25(OH)D and 1,25(OH)2D3 are 
usually associated with higher rates of albuminuria 
in CKD patients.29 Liu et al.30 evaluated the effects of 
three months of calcitriol therapy in patients with IgA 
nephropathy, while de Zeeuw et al.11 evaluated the 
effects of paricalcitol in type 2 diabetes individuals 
in the VITAL study. These studies reported sustained 
post-treatment reductions in proteinuria and 
albuminuria, respectively, without an increase in 
adverse events such as hypercalcemia.
However, both drugs may be associated with adverse 
events that cannot be neglected, such as hypercalcemia, 
hypercalciuria, and hypoparathyroidism; in the VITAL 
study, for example, a higher proportion of patients 
using 2 μg of paricalcitol was withdrew from the study 
because of adverse events (p = 0.018 vs. placebo).11 
Agarwal et al.31 performed a randomized placebo-
controlled trial of paricalcitol in patients with stages 
3 or 4 CKD and secondary hyperparathyroidism. The 
authors reported a significant reduction in proteinuria, 
even after adjusting for several covariates such as 
diabetes mellitus and use of angiotensin blockers. 
Alborzi et al.10 identified similar effects of paricalcitol 
on albuminuria of patients with stages 2 or 3 CKD, 
regardless of its effects on parathyroid hormone 
suppression.
These data were confirmed in a recent systematic 
review, which found that calcitriol and paricalcitol 
reduced proteinuria by 16% in patients with CKD, 
while controls showed a 6% increase.32 As our 
patients have more advanced chronic kidney damage 
and higher levels of proteinuria, we could not 
demonstrate such an association, probably because 
serum 25(OH)D and albuminuria correlate at earlier 
stages of kidney disease.
The protective effects of vitamin D on the loss 
of glomerular filtration rate and the progression 
of kidney disease are yet to be demonstrated in 
clinical trials. De Boer et al.5 evaluated 1705 elderly 
subjects with predominantly normal kidney function, 
and found that a 10 ng/mL reduction in the serum 
concentration of 25(OH)D increased the risk of 
rapid GFR loss by 25%. In the present study, eGFR 
decreased significantly by a mean of 4 ml/min/1.73 
m2 following six months of cholecalciferol treatment. 
These findings are in agreement with those of Liu 
et al.,30 who reported an increase in serum creatinine 
and a decrease in eGFR in calcitriol-treated patients. 
However, the effects of vitamin D on the creatinine 
metabolism of patients with CKD must also be 
considered. Vitamin D is known to increase creatinine 
generation leading to higher serum creatinine levels, 
with no real effect on GFR.33,34 Clinical trials in early 
stages of CKD are still required to determine the long-
term renoprotective effects of vitamin D on renal 
function and patient morbidity and mortality.
To evaluate the distribution of each urine podocyte 
mRNA according to baseline and post treatment serum 
25(OH)D, the tertiles of serum 25(OH)D (< 23, 23-
30 and > 30 ng/mL) were determined. Theoretically, 
we would expect higher levels of podocyte byproducts 
in urine in the lower tertile of vitamin D at baseline. 
Conversely, lower levels of podocyte mRNAs in 
the highest tertile of 25(OH)D would be assumed 
after cholecalciferol supplementation, suggesting a 
putative effect of vitamin D on “morphologic and 
functional recovery” of glomerular epithelial cells, 
and consequently lower podocyturia. However, the 
erratic distribution of podocyte mRNAs throughout 
the tertiles did not confirm our main hypothesis.
It is possible that a higher threshold for 25(OH)
D levels or a longer supplementation period may 
be required to restore gene transcription and the 
expression of podocyte proteins in the glomerulus. 
In addition, cholecalciferol replacement may not be 
effective to reduce proteinuria in the advanced CKD. 
Otherwise, the degree of podocyte injury in more 
advanced CKD, which is associated with a higher 
percentage of glomerular sclerosis, may result in 
irreversible podocyte damage and cell death through 
apoptotic or non-apoptotic mechanisms.
There are several limitations in this study. The small 
sample size and the absence of a control group might 
preclude any conclusions regarding the actual effects 
of cholecalciferol on podocyturia, and the course of 
urine podocyte mRNAs during the progression of 
CKD. Another limitation is the heterogeneity of the 
study group regarding different etiologies and stage 
of CKD, as both of which may have implications for 
podocyte injury and recovery. However, the method 
used to detect podocyte injury in the present sample, 
that is, quantification of podocyte-associated mRNAs 
in urine, offers an accurate and non-invasive, albeit 
indirect, measure of podocyturia, with none of the 
risks associated with invasive methods such as renal 
biopsy.
The effects of 1,25(OH)2D3 are more likely to be 
influenced by the serum 25(OH)D concentration after 
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the supplementation (which may need to reach a certain 
cutoff before any effect is seen), a longer duration of 
treatment, and/or the beginning of vitamin D at earlier 
stages of CKD, rather than the baseline 25(OH)D levels 
itself. In addition, the use of active forms of vitamin D or 
its analogous such as calcitriol or paricalcitol, instead of 
the substrate cholecalciferol, maybe needed to maximize 
the direct activation of the VDR in podocyte cells leading 
to a biologic response.
We can also consider that cholecalciferol is 
not properly converted to active calcitriol in more 
advanced stages of CKD. This lower conversion 
of native vitamin D to calcitriol can be related to 
inhibition of 1-alpha-hydroxilase in the kidney due 
to higher levels of fibroblast growth factor 23 via 
activation of the ERK1/2 signaling pathway35 besides 
the loss of functional renal mass.
conclusIon
In conclusion, six months of cholecalciferol 
supplementation had no effect on urine podocyte mRNA 
profile, proteinuria or kidney function in patients with 
CKD stages 2 to 4. However, patients with higher 
25(OH)D levels showed a trend in reduction of nephrin 
and podocin mRNAs following treatment. Further 
studies are needed to evaluate the protective effects of 
vitamin D or its analogues on podocytes, perhaps at 
earlier stages of CKD and with a longer follow-up.
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